key: cord-0989331-xwo3t3l4
authors: Vitali, Claudio; Minniti, Antonina; Del Papa, Nicoletta
title: Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19 infection
date: 2020-05-05
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.05.002
sha: 3ab5a402da818b652a76f24bee3ae0a1ed8ad205
doc_id: 989331
cord_uid: xwo3t3l4

nan

CV, a 70 y.o. man, became feverish in the evening of March 11 th , but fever completely disappeared the day after. In the following days CV complained of sore throat, severe myalgia, weakness and anorexia. Cough or shortness of breath were not present. Since CV lives in Milan and is a medical doctor having contacts with a lot of people, a SARS-CoV-2 infection was supposed. In accordance with the recommendations of the National and Regional Health Authority for the pandemic outbreak, CV decided to stay at home, assuming only intermittent therapy to improve myalgia (diclofenac). A week after the symptoms progressively improved and only mild sore throat persisted.

On April 2 nd dyspnoea, together with increased cardiac rate (110-120 bpm), suddenly The occurrence of a hypercoagulable state in the course of critically ill ICU patients with COVID-19 is an emerging issue [1] . This may induce al large variety of intravascular thrombotic phenomena ranging from fatal disseminated intravascular coagulation (DIC) to a more limited venous and arterial thrombosis, namely PE. It has been suggested that many deaths during COVID-19 in patients requiring intensive care unit (ICU) admission could be ascribed to this coagulopathy, and overall to incidental DIC in patients with severe pneumonitis [1] . In the Wuham cohort, during pandemic outbreak, the presence of coagulation cascade activation was noted [1] , and, in a retrospective study [3] , it was reported that prophylactic heparin treatment in ICU-admitted patients with proven COVID-19 pneumonia reduced the mortality rate in comparison to the patients that did not receive it.

It has been suggested that infection-related release of large amounts of inflammatory cytokines can cause an endothelial damage, activate the coagulation cascade, and consequently may predispose to thrombotic events that may also occur in pulmonary vasculature [4] . This event may probably contribute to the progression of pulmonary dysfunction and increase the mortality rate in these patients.

These data pushed the International Society on Thrombosis and Haemostasis to propose a guidance on diagnostic and therapeutic approach to coagulopathy in COVID-19 infection [1] . These guidelines suggest to perform D-dimer, prothrombin time, and platelet count in all patients who present with COVID-19, and to admit to the hospital those patients with important signs of coagulopathy (namely very high levels of D-dimer), also in absence of other concerns. In view of the risk of occurrence of such a hypercoagulable state, the use of prophylactic dose of low molecular weight heparin in all the patients requiring hospitalization for COVID-19, including those not requiring ICU has been proposed [1] . A recent study on ICU-admitted patients with COVID-19 pneumonia has shown that thrombotic events were recorded in 31% of them with a large prevalence of PE (81%). It is worth noting that all of these patients received thromboprophylaxis [5] . As a consequence of these data, an early initiation of therapeutic anticoagulation in critically ill patients with significant coagulation abnormalities could be indicated [4, 6] . Furthermore, a more extensive use of CT pulmonary angiography in order to document incidental PE should be considered in all hospitalized patients with laboratory signs of coagulopathy [7] .

The present case report may suggest some additional considerations regarding the therapeutic and clinical approach to SARS-CoV-2-infected patients. 

ISTH interim guidance on recognition and management of coagulopathy in COVID 19

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

ISTH interim guidance on recognition and management of coagulopathy in COVID 19: a comment

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Where we stand with antithrombotic therapy in patients with COVID-19

Pulmonary embolism in patients with COVID-19: time to change the paradigm of computed tomography